CN1384733A - 分散性得到改进的干粉组合物 - Google Patents
分散性得到改进的干粉组合物 Download PDFInfo
- Publication number
- CN1384733A CN1384733A CN00814989A CN00814989A CN1384733A CN 1384733 A CN1384733 A CN 1384733A CN 00814989 A CN00814989 A CN 00814989A CN 00814989 A CN00814989 A CN 00814989A CN 1384733 A CN1384733 A CN 1384733A
- Authority
- CN
- China
- Prior art keywords
- dry powder
- compositions
- tripeptides
- dipeptides
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Description
样品 | 表面张力(ST)mN/m(毫牛/米) | 时间/秒 | STmN/m | 时间/秒 | STmN/m | 时间/秒 |
水空白-1 | 72.6 | 49 | 72.6 | 100 | 72.6 | 194 |
水空白-2 | 72.5 | 49 | 72.5 | 100 | 72.4 | 194 |
水空白-3 | 72.5 | 49 | 72.4 | 100 | 72.4 | 194 |
1%棉子糖-1 | 72 | 49 | 72 | 100 | 72 | 194 |
1%棉子糖-2 | 72 | 49 | 72 | 100 | 72 | 194 |
1%棉子糖-3 | 72 | 49 | 72 | 100 | 72 | 194 |
0.2%三丙氨酸-1 | 72.4 | 49 | 72.4 | 100 | 72.3 | 194 |
0.2%三丙氨酸-2 | 72.2 | 49 | 72.2 | 100 | 72.2 | 194 |
0.2%三丙氨酸-3 | 72.3 | 49 | 72.2 | 100 | 72.2 | 194 |
0.2%三谷氨酸盐-1 | 72.1 | 49 | 72.1 | 100 | 72.1 | 194 |
0.2%三谷氨酸盐-2 | 72.4 | 49 | 72.4 | 100 | 72.4 | 194 |
0.2%三谷氨酸盐-3 | 72.4 | 49 | 72.4 | 100 | 72.3 | 194 |
0.2%二丙氨酸-1 | 72 | 49 | 72 | 100 | 71.9 | 194 |
0.2%二丙氨酸-2 | 72 | 49 | 71.9 | 100 | 71.9 | 194 |
0.2%二丙氨酸-3 | 72.1 | 49 | 72.1 | 100 | 72.1 | 194 |
0.2%二亮氨酸-1 | 58.4 | 49 | 58.1 | 100 | 57.9 | 194 |
0.2%二亮氨酸-2 | 58.7 | 49 | 58.3 | 100 | 58.2 | 194 |
0.2%二亮氨酸-3 | 60.1 | 49 | 59.8 | 100 | 59.7 | 194 |
0.2%三亮氨酸-1 | 51 | 49 | 50.9 | 100 | 50.9 | 194 |
0.2%三亮氨酸-2 | 51 | 49 | 50.8 | 100 | 50.7 | 194 |
0.2%三亮氨酸-3 | 51 | 49 | 50.8 | 100 | 50.7 | 194 |
0.2%S.降钙素-1 | 48.7 | 49 | 48.6 | 100 | 48.5 | 194 |
0.2%S.降钙素-2 | 48.4 | 49 | 48.4 | 100 | 48.4 | 194 |
0.2%S.降钙素-3 | 48.4 | 49 | 48.4 | 100 | 48.4 | 194 |
样品 | STmN/m | 时间/秒 | STmN/m | 时间/秒 | ST mN/m | 时间/秒 |
水空白-1 | 72 | 49 | 71.8 | 100 | 71.7 | 194 |
水空白-2 | 72.2 | 49 | 72.2 | 100 | 72.2 | 194 |
水空白-3 | 71.5 | 49 | 71.6 | 100 | 71.6 | 194 |
0.2%二异亮氨酸-1 | 67.6 | 49 | 67.2 | 100 | 67 | 194 |
0.2%二异亮氨酸-2 | 68 | 49 | 67.8 | 100 | 67.6 | 194 |
0.2%二异亮氨酸-3 | 67.7 | 49 | 71.6 | 100 | 71.6 | 194 |
0.2%二缬氨酸-1 | 71.7 | 49 | 71.6 | 100 | 71.6 | 194 |
0.2%二缬氨酸-2 | 71.6 | 49 | 71.6 | 100 | 71.6 | 194 |
0.2%二缬氨酸-3 | 71.7 | 49 | 71.6 | 100 | 71.6 | 194 |
0.2%三缬氨酸-1 | 68.8 | 49 | 68.8 | 100 | 68.8 | 194 |
0.2%三缬氨酸-2 | 68.8 | 49 | 68.7 | 100 | 68.7 | 194 |
0.2%三缬氨酸-3 | 68.7 | 49 | 68.7 | 100 | 68.7 | 194 |
样品 | STmN/m | 时间/秒 | STmN/m | 时间/秒 | STmN/m | 时间/秒 |
1%棉子糖(pH4)-1 | 71.4 | 49 | 71.4 | 100 | 71.4 | 194 |
1%棉子糖(pH4)-2 | 71.1 | 49 | 71.1 | 100 | 71.1 | 194 |
1%棉子糖(pH4)-3 | 71.1 | 49 | 71.1 | 100 | 71.1 | 194 |
1%棉子糖(pH7)-1 | 71.1 | 49 | 71.1 | 100 | 71.1 | 194 |
1%棉子糖(pH7)-2 | 71.1 | 49 | 71.1 | 100 | 71.1 | 194 |
1%棉子糖(pH7)-3 | 71.1 | 49 | 71.1 | 100 | 71.1 | 1 94 |
水空白-1 | 72.1 | 49 | 72 | 100 | 72 | 194 |
水空白-2 | 72.2 | 49 | 72.1 | 100 | 72 | 194 |
水空白-3 | 72.2 | 49 | 72.1 | 100 | 72 | 194 |
0.05%leu3(pH4)-1 | 59.9 | 49 | 59.8 | 100 | 59.7 | 194 |
0.05%leu3(pH4)-2 | 60.4 | 49 | 60.3 | 100 | 60.2 | 194 |
0.05%leu3(pH4)-3 | 60.4 | 49 | 60.3 | 100 | 60.2 | 194 |
0.2%leu3(pH4)-1 | 51.4 | 49 | 51.2 | 100 | 51.1 | 194 |
0.2%leu3(pH4)-2 | 51.4 | 49 | 51.3 | 100 | 51.2 | 194 |
0.2%leu3(pH4)-3 | 51.4 | 49 | 51.2 | 100 | 51.1 | 194 |
0.6%leu3(pH4)-1 | 44.2 | 49 | 44.1 | 100 | 44 | 194 |
0.6%leu3(pH4)-2 | 44.3 | 49 | 44.2 | 100 | 44.2 | 194 |
0.6%leu3(pH4)-3 | 44.2 | 49 | 44.2 | 100 | 44.1 | 194 |
0.05%leu3(pH7)-1 | 60.1 | 49 | 59.8 | 100 | 59.7 | 194 |
0.05%leu3(pH7)-2 | 60 | 49 | 59.8 | 100 | 59.7 | 194 |
0.05%leu3(pH7)-3 | 60.2 | 49 | 60 | 100 | 59.8 | 194 |
0.2%leu3(pH7)-1 | 51 | 49 | 50.8 | 100 | 50.7 | 194 |
0.2%leu3(pH7)-2 | 50.9 | 49 | 50.7 | 100 | 50.6 | 194 |
0.2%leu3(pH7)-3 | 50.7 | 49 | 50.5 | 100 | 50.4 | 194 |
0.6%leu3(pH7)-1 | 43.7 | 49 | 43.7 | 100 | 43.6 | 194 |
0.6%leu3(pH7)-2 | 43.8 | 49 | 43.7 | 100 | 43.7 | 194 |
0.6%leu3(pH7)-3 | 43.8 | 49 | 43.7 | 100 | 43.7 | 194 |
水空白-5 | 71.7 | 49 | 71.7 | 100 | 71.6 | 194 |
水空白-6 | 72.2 | 49 | 72.1 | 100 | 72.1 | 194 |
样品 | STmN/m | 时间/秒 | STmN/m | 时间/秒 | STmN/m | 时间/秒 |
水空白-5 | 69.2 | 49 | 69.2 | 100 | 69.2 | 194 |
1%棉子糖(pH4)-1 | 67.9 | 49 | 68 | 100 | 68 | 194 |
1%棉子糖(pH4)-2 | 68.2 | 49 | 68.2 | 100 | 68.2 | 194 |
1%棉子糖(pH4)-3 | 68 | 49 | 68 | 100 | 68.1 | 194 |
1%棉子糖(pH7)-1 | 68.3 | 49 | 68.3 | 100 | 68.3 | 194 |
1%棉子糖(pH7)-2 | 68.4 | 49 | 68.4 | 100 | 68.4 | 194 |
1%棉子糖(pH7)-3 | 68.4 | 49 | 68.4 | 100 | 68.4 | 194 |
含有棉子糖的Leu3制剂,使总固含量为1% | ||||||
0.05%leu3(pH4)-1 | 57.1 | 49 | 57 | 100 | 57 | 194 |
0.05%leu3(pH4)-2 | 58.1 | 49 | 57.9 | 100 | 57.8 | 194 |
0.05%leu3(pH4)-3 | 58 | 49 | 57.8 | 100 | 57.8 | 194 |
0.2%leu3(pH4)-1 | 47.9 | 49 | 47.5 | 100 | 47.4 | 194 |
0.2%leu3(pH4)-2 | 47.2 | 49 | 47.2 | 100 | 47.3 | 194 |
0.2%leu3(pH4)-3 | 47.9 | 49 | 47.3 | 100 | 47.1 | 194 |
0.6%leu3(pH4)-1 | 40.9 | 49 | 40.9 | 100 | 40.8 | 194 |
0.6%leu3(pH4)-2 | 41.1 | 49 | 41 | 100 | 40.9 | 194 |
0.6%leu3(pH4)-3 | 41.1 | 49 | 41 | 100 | 40.8 | 194 |
0.05%leu3(pH7)-1 | 58.5 | 49 | 58.4 | 100 | 58.4 | 194 |
0.05%leu3(pH7)-2 | 58.2 | 49 | 58.2 | 100 | 58.1 | 194 |
0.05%leu3(pH7)-3 | 58.2 | 49 | 58.1 | 100 | 58.1 | 194 |
0.2%leu3(pH7)-1 | 58.5 | 49 | 58.4 | 100 | 58.4 | 194 |
0.2%leu3(pH7)-2 | 58.2 | 49 | 58.2 | 100 | 58.1 | 194 |
0.2%leu3(pH7)-3 | 58.2 | 49 | 58.1 | 100 | 58.1 | 194 |
25℃ | 45℃ | 25℃ | 45℃ | ||||
真实值 | 真实值 | 外推值 | 外推值 | ||||
样品 | 浓度mg/ml | 平均值 | SD | 平均值 | SD | 浓度为2mg/ml | 浓度为2mg/ml |
二聚物 | |||||||
Leu-2 | 13.60 | 46.6 | 0.6 | 42.7 | 0.3 | 60.4 | 52.4 |
4.53 | 54.9 | 0.5 | 48.2 | 0.1 | |||
1.51 | 61.5 | 0.6 | 53.2 | 0.1 | |||
Leu-Val | 8.80 | 59.1 | 0.2 | 55.7 | 0.3 | 67.2 | 62.3 |
2.93 | 65 | 0.2 | 60.4 | 0.0 | |||
0.98 | 69.2 | 0.4 | 64.2 | 0.2 | |||
Leu-Tyr | 6.40 | 62.2 | 0.1 | 59.5 | 0.3 | 68.3 | 67.3 |
2.13 | 68.0 | 0.1 | 65.6 | 0.3 | |||
0.71 | 71.5 | 0 | 68.0 | 0.1 | |||
Val-Leu | 7.80 | 68 | 0 | 63.5 | 0.2 | 69.8 | 65.3 |
2.60 | 69.5 | 0.1 | 65.0 | 0.2 | |||
0.87 | 70 | 0.5 | 65.5 | 0.0 | |||
Val-Ile | 10.00 | 66.1 | 0 | 61.9 | 0.2 | 70.3 | 65.8 |
3.33 | 70.1 | 0.3 | 65.3 | 0.1 | |||
1.11 | 71.6 | 0.2 | 66.3 | 0.2 | |||
Leu | TBD | 56.7 | 0.3 | 54.7 | 0.2 | ||
66.3 | 0.2 | 61.4 | 0.2 | ||||
三聚物 | 70.8 | 0.2 | 64.2 | 0.0 | |||
Leu-Tyr-Leu | 2.90 | 44.7 | 0.1 | 40.8 | 0.0 | 47.9 | 44.7 |
0.97 | 51.6 | 0.1 | 49.1 | 0.1 | |||
0.32 | 58.4 | 0.1 | 55.4 | 0.3 | |||
Leu-Phe-Leu | 6.10 | 41.5 | 0.2 | 39.3 | 0.0 | 48.3 | 46.2 |
2.03 | 48.3 | 0 | 46.2 | 0.1 | |||
0.68 | 54.7 | 0.1 | 53.6 | 0.1 | |||
Leu-3 | 6.10 | 42.4 | 0 | 38.9 | 0.2 | 49.7 | 46.3 |
2.03 | 49.7 | 0 | 46.3 | 0.3 | |||
0.68 | 56.9 | 0 | 52.8 | 0.6 | |||
Leu-Leu-Ala | 6.80 | 39.9 | 0.5 | 48.4 | 0.2 | 46.6 | 49.8 |
2.27 | 43.5 | 0.8 | 48.2 | 4.3 | |||
0.76 | 60.7 | 0.4 | 58.3 | 0.5 | |||
Ala-Val-Leu | 8.70 | 55.7 | 0.2 | 53.8 | 0.0 | 65 | 58.9 |
2.90 | 62.8 | 0.5 | 57.7 | 0.2 | |||
0.97 | 67.5 | 0.5 | 60.3 | 0.1 |
批号 | 组成 | 释放剂量,%平均值,n=10 | RSD,% | MMAD(μm) | FPD |
R97190 | 30%PTH70%甘露醇 | 62 | 4 | - | - |
30%PTH70%棉子糖 | 66 | 9 | - | - | |
R97191 | 75%PTH25%甘露醇 | 51 | 3 | - | - |
30%PTH70%leu | 78 | - | 2.43 | 0.58 | |
30%PTH70%三亮氨酸 | 83 | - | 2.63 | 0.45 |
制剂 | 释放剂量,% | Tg,℃ |
2%沙丁醇胺98%棉子糖 | 31 | 102.2 |
2%沙丁醇胺5%亮氨酸棉子糖 | 31 | 88.57 |
2%沙丁醇胺20%亮氨酸棉子糖 | 34 | 93.1 |
2%沙丁醇胺60%亮氨酸棉子糖 | 74 | 96.6 |
2%沙丁醇胺5%三亮氨酸棉子糖 | 62 | 85.3 |
2%沙丁醇胺20%三亮氨酸棉子糖 | 78 | 95.9 |
2%沙丁醇胺60%三亮氨酸棉子糖 | 82 | 88.6 |
制剂 | FPD | MMAD,微米 |
2%沙丁醇胺60%亮氨酸棉子糖 | 0.56 | 2.43 |
2%沙丁醇胺20%三亮氨酸棉子糖 | 0.59 | 2.43 |
制剂 | 释放剂量 | FPD | Tg,℃ |
5%S.降钙素95%棉子糖 | 48 | 0.30 | 89.9 |
5%S.降钙素5%亮氨酸棉子糖 | 47 | 0.31 | 89.3 |
5%S降钙素20%亮氨酸棉子糖 | 50 | 0.28 | 82.9 |
5%S.降钙素40%亮氨酸棉子糖 | 48 | 0.29 | 82.3 |
5%S.降钙素60%亮氨酸棉子糖 | 53 | 0.22 | 80.5 |
5%S.降钙素80%亮氨酸棉子糖 | 64 | 0.29 | 74.5 |
5%S.降钙素5%三亮氨酸棉子糖 | 58 | 0.46 | 89 |
5%S.降钙素20%三亮氨酸棉子糖 | 72 | 0.50 | 91.1 |
5%S.降钙素40%三亮氨酸棉子糖 | 76 | 0.46 | 83.4 |
5%S.降钙素60%三亮氨酸棉子糖 | 84 | 0.49 | 94.3 |
5%S.降钙素80%三亮氨酸棉子糖 | 86 | 0.49 | 115.2 |
制剂 | MMAD |
5%S.降钙素20%亮氨酸棉子糖 | 3.39 |
5%S.降钙素20%三亮氨酸棉子糖 | 2.87 |
批 号 | 喷雾干燥前的定量组成 | 水分含量 | MMAD(μm) | 释放剂量 |
(1)1326-16 | 盐酸环丙氟哌酸 1136mg去离子水 113ml固体产物: 100%环丙氟哌酸 | 1.4% | 2.8 | 42%(RSD=8) |
(2)1326-29 | 盐酸环丙氟哌酸 2047mg去离子水 200ml氢氧化钠 适量至pH=12固体产物: 100%环丙氟哌酸 | 3.2% | 4.5 | 51%(RSD=7) |
(3)1300-MG-7 | 盐酸环丙氟哌酸 1995mg甲醇 100ml去离子水 100ml固体产物: 100%环丙氟哌酸 | 1.2% | 2.9 | 33%(RSD=13) |
批 号 | 定量组成 | 水分含量 | MMAD(μm) | 释放剂量 |
1326-31 | 硫酸庆大霉素 2076mg去离子水 200ml盐酶 适量至pH=5 | 4.1%1 | 3.0 | 37%(RSD3=6) |
1326-32 | 硫酸庆大霉素 2053mg去离子水 200ml氢氧化钠 适量至pH=10 | 1.1%1 | 2.4 | 40%(RSD=14) |
1300-MG-11 | 硫酸庆大霉素 2012mg乙醇 40ml去离子水 160ml | 4.8%2 | 3.0 | 45%(RSD=10) |
1300-MG-9 | 硫酸奈替米星 1626mg去离子水 163ml | 4.2% | 3.2 | 47%(RSD=8) |
1300-MG-14 | 硫酸奈替米星 1512mg乙醇 30ml去离子水 120ml | 5.1% | 2.9 | 39%(RSD=7) |
制 剂 | 收率,% | MMAD,μm | FPD(<3.3μm) | ED,% |
95%Cipro(环丙氟哌酸)5%Leu-3 | 64.2 | 2.43 | 0.57 | 77.7 |
75%Cipro25%Leu-3 | N.A. | 2.65 | N.A. | 83.0 |
45%Cipro55%Leu-3 | 55.0 | 2.62 | 0.48 | 70.7 |
95%Gent.(庆大霉素)5%Leu-3 | 61.4 | 2.15 | 0.66 | 75.7 |
75%Gent.25%Leu-3 | 52.0 | 2.25 | 0.66 | 93.9 |
55%Gent.45%Leu-3 | 54.2 | 2.51 | 0.51 | 87.3 |
95%Netil.(奈替米星)5%Leu-3 | 62.0 | 2.08 | 0.58 | 82.4 |
75%Netil25%Leu-3 | 50.0 | 2.14 | 0.66 | 91.3 |
55%Netil.45%Leu-3 | 40.0 | 2.73 | 0.49 | 90.4 |
批号 | 组成 | ED,%平均值(n=10) | RSD,% | MMAD,μm | FPD,% | 收率,% | <5μm的比例,% |
RB19 | 10%IFN-β(β-干扰素)45%Leu-345%HES | 81 | 7 | 3.2 | 48 | 56 | 79 |
RB21 | 10%IFN-β45%Leu-345%Raff.(棉子糖) | 80 | 6 | 2.9 | 46 | 61 | 85 |
RB24 | 10%IFN-β90%Leu-3 | - | - | - | - | 9* | - |
RB27 | 10%IFN-β67.5%Leu-322.5%Raff. | 74 | 4 | 2.9 | 49 | 40 | 81 |
RB29 | 10%IFN-β45%Leu-345%HES | 79 | 5 | 3.2 | 41 | 50 | 83 |
RB36 | 10%IFN-β22.5%Leu-367.5%Raff. | 87 | 3 | - | - | 61 | - |
99320 | 10%IFN-β90%Raff. | 64 | - | - | - | - | - |
制 剂 | 释放剂量(RSD) | MMAD |
93%因子IX/7%柠檬酸钠 | 57(5%) | - |
37%因子IX/3%柠檬酸钠/60%亮氨酸 | 78(3%) | 2.9 |
56%因子IX/4%柠檬酸钠/40%三亮氨酸 | 89(5%) | 2.7 |
制剂编号组 成 | 包装的储存条件无第二包装无干燥剂40℃/环境RH | %纯度(面积) | %释放剂量(rsd) | 细粒子剂量(FPD)<3.3μm | MMAD(μm) | %重量变化(TGA) |
R9948430%PTH/70%亮氨酸 | 初始 | 97.0 | 79.6(3) | 0.58 | 2.5 | 1.4 |
4周 | n/a | 74.9(5) | n/a | n/a | 1.7 | |
6周 | n/a | 75.2(6) | n/a | n/a | n/a | |
8周 | 95.2* | 78.8(6) | 0.55 | 2.4 | 2.2 | |
12周 | n/a | 78.6(3) | n/a | n/a | TBD | |
R9948530%PTH/70%三亮氨酸 | 初始 | 97.1 | 79.4 | 0.45 | 2.9 | 2.6 |
4周 | n/a | 75.8 | n/a | n/a | 2.4 | |
6周 | n/a | 81.6 | n/a | n/a | n/a | |
8周 | 94.8 | 81.6 | 0.44 | 2.9 | 2.4 | |
12周 | n/a | 在BP之外 | n/a | 在BP之外 | 在BP之外 |
批号 | 制剂(%重量/重量) | ESCA结果(%重量/重量) | |
R99282 | sCal | 5 | 53 |
pH7 | 亮氨酸 | 0 | |
棉子糖 | 95 | 47 | |
R99283 | sCal | 5 | 11 |
pH7 | 亮氨酸 | 5 | 52 |
棉子糖 | 90 | 38 | |
R99284 | sCal | 5 | 39 |
pH7 | 亮氨酸 | 20 | 28 |
棉子糖 | 75 | 33 | |
R99286pH7 | sCal | 5 | 26 |
亮氨酸 | 80 | 64 | |
棉子糖 | 15 | 9 |
批号 | 制剂(%重量/重量) | ESCA结果(%重量/重量) | |
R99337 | 亮氨酸-2 | 5 | 28.7 |
pH7 | 棉子糖 | 95 | 71.3 |
R99338 | 亮氨酸-2 | 20 | 44.4 |
pH7 | 棉子糖 | 80 | 55.9 |
R99339 | 亮氨酸-2 | 60 | 94.9 |
pH7 | 棉子糖 | 40 | 5.1 |
R99340 | 亮氨酸-3 | 20 | 97.1 |
pH7 | 棉子糖 | 80 | 2.9 |
R99342 | 丙氨酸-3 | 20 | 41.3 |
pH7 | 棉子糖 | 80 | 58.7 |
批号 | 制剂(%重量/重量) | ESCA结果(%重量/重量) | |
R99435pH4 | SCal | 5 | 36.6 |
亮氨酸-3 | 0 | 0 | |
棉子糖 | 95 | 63.4 | |
R99436 | Scal | 5 | 17.9 |
pH4 | 亮氨酸-3 | 5 | 7.0 |
棉子糖 | 90 | 75.1 | |
R99437 | Scal | 5 | 46.4 |
pH4 | 亮氨酸-3 | 20 | 24.2 |
棉子糖 | 75 | 29.4 | |
R99438pH4 | Scal | 5 | 22.7 |
亮氨酸-3 | 40 | 74.8 | |
棉子糖 | 55 | 2.5 | |
R99439pH4 | SCal | 5 | 16.4 |
亮氨酸-3 | 60 | 81.6 | |
棉子糖 | 35 | 2.0 |
Claims (40)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16245199P | 1999-10-29 | 1999-10-29 | |
US60/162,451 | 1999-10-29 | ||
US16423699P | 1999-11-08 | 1999-11-08 | |
US60/164,236 | 1999-11-08 | ||
US17276999P | 1999-12-20 | 1999-12-20 | |
US60/172,769 | 1999-12-20 | ||
US17838300P | 2000-01-27 | 2000-01-27 | |
US17841500P | 2000-01-27 | 2000-01-27 | |
US60/178,383 | 2000-01-27 | ||
US60/178,415 | 2000-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1384733A true CN1384733A (zh) | 2002-12-11 |
CN1188111C CN1188111C (zh) | 2005-02-09 |
Family
ID=27538661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008149895A Expired - Fee Related CN1188111C (zh) | 1999-10-29 | 2000-04-12 | 分散性得到改进的干粉组合物 |
Country Status (21)
Country | Link |
---|---|
US (4) | US6518239B1 (zh) |
EP (2) | EP1223915B1 (zh) |
JP (2) | JP4859320B2 (zh) |
KR (1) | KR100702878B1 (zh) |
CN (1) | CN1188111C (zh) |
AT (2) | ATE313318T1 (zh) |
AU (1) | AU775565B2 (zh) |
CA (1) | CA2389219C (zh) |
CY (1) | CY1110136T1 (zh) |
DE (2) | DE60025019T2 (zh) |
DK (2) | DK1666028T3 (zh) |
ES (2) | ES2254164T3 (zh) |
HK (1) | HK1092687A1 (zh) |
HU (1) | HU229310B1 (zh) |
IL (2) | IL149085A0 (zh) |
MX (1) | MXPA02004193A (zh) |
NO (1) | NO332144B1 (zh) |
NZ (1) | NZ518401A (zh) |
PT (1) | PT1666028E (zh) |
TW (1) | TWI310688B (zh) |
WO (1) | WO2001032144A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105451716A (zh) * | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CN109310622A (zh) * | 2016-06-30 | 2019-02-05 | 菲利普莫里斯生产公司 | 尼古丁颗粒和组合物 |
WO2022148418A1 (zh) * | 2021-01-08 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
Families Citing this family (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
EP0679088B1 (en) * | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
EP2036541A1 (en) * | 1994-03-07 | 2009-03-18 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
MX9605717A (es) * | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
ATE545652T1 (de) * | 1999-06-29 | 2012-03-15 | Mannkind Corp | Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien |
US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
WO2001027103A1 (en) | 1999-10-08 | 2001-04-19 | Smithkline Beecham Corporation | Fab i inhibitors |
DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
EP1292347B1 (en) * | 2000-02-11 | 2009-10-07 | Respironics Respiratory Drug Delivery (UK) Ltd. | Drug delivery apparatus |
US8820316B2 (en) * | 2000-02-11 | 2014-09-02 | Respironics Respiratory Drug Delivery (Uk) Ltd | Drug delivery apparatus |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
IL153705A0 (en) | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
WO2002009674A2 (en) * | 2000-07-28 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
TWI283182B (en) * | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
CA2432319A1 (en) * | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
US7214364B2 (en) * | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
DE122011100043I1 (de) * | 2000-12-27 | 2011-12-15 | Gilead Sciences Inc | Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen. |
US20020114843A1 (en) * | 2000-12-27 | 2002-08-22 | Ramstack J. Michael | Preparation of microparticles having improved flowability |
US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
JP4387804B2 (ja) * | 2001-04-06 | 2009-12-24 | アフィニアム・ファーマシューティカルズ・インコーポレイテッド | FabI阻害剤 |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
DE60219164T2 (de) * | 2001-06-15 | 2007-07-12 | Takeda Pharmaceutical Co. Ltd. | Polypeptid mit zelltodhemmender wirkung |
EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
WO2003035028A1 (en) * | 2001-10-19 | 2003-05-01 | Nektar Therapeutics | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
WO2003035051A2 (en) * | 2001-10-19 | 2003-05-01 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
AUPR879601A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
JP2005514393A (ja) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | アミノグリコシドの肺への供給 |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
DE10206770A1 (de) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
PT1494732E (pt) * | 2002-03-20 | 2008-03-20 | Mannkind Corp | Aparelho de inalação |
EP1487411B1 (en) * | 2002-03-20 | 2019-01-02 | Civitas Therapeutics, Inc. | Inhalable sustained therapeutic formulations |
GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
CN100434440C (zh) * | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
SI1575951T1 (sl) | 2002-12-06 | 2014-10-30 | Debiopharm International Sa Forum "Apres-Demain" | Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji |
AR042454A1 (es) * | 2002-12-13 | 2005-06-22 | Otsuka Pharma Co Ltd | Sistema de inhalacion de polvo para la administracion transpulmonar |
JP2004238392A (ja) * | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
KR101173696B1 (ko) * | 2003-02-10 | 2012-08-13 | 바이엘 파마 악티엔게젤샤프트 | 플루오로퀴놀론의 국소 적용에 의한 호흡 기관의 세균성질환의 치료 |
DE602004016831D1 (de) | 2003-03-17 | 2008-11-13 | Affinium Pharm Inc | Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend |
JP2007524607A (ja) * | 2003-04-09 | 2007-08-30 | ワイス | 凝固因子の吸入による血友病処置 |
EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
JP2007516149A (ja) | 2003-05-21 | 2007-06-21 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 基板温度の均一性を制御する方法、および、内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット |
EP1635786A2 (en) * | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
TW200510412A (en) * | 2003-08-12 | 2005-03-16 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
NZ545412A (en) * | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
US20050054665A1 (en) * | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
EP1663164A2 (en) * | 2003-09-15 | 2006-06-07 | Vectura Limited | Methods for preparing pharmaceutical compositions |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
ES2544477T3 (es) * | 2003-10-03 | 2015-08-31 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con alcoxi |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
CN1906192A (zh) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 羟胺取代的咪唑环化合物 |
AU2004291101A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
WO2005051317A2 (en) * | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
DE10358387A1 (de) * | 2003-12-13 | 2005-07-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
CA2549730C (en) * | 2003-12-16 | 2012-02-14 | Nektar Therapeutics Al, Corporation | Chemically modified small molecules |
US8802853B2 (en) * | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
CA2551749C (en) | 2003-12-31 | 2014-02-11 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2005067898A2 (en) | 2004-01-07 | 2005-07-28 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
US20050153874A1 (en) * | 2004-01-12 | 2005-07-14 | Mannkind Corporation | Method of reducing serum proinsulin levels in type 2 diabetics |
WO2005088655A1 (en) * | 2004-03-12 | 2005-09-22 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A magnetoresistive medium |
EP1740154B1 (en) * | 2004-03-12 | 2009-06-17 | Biodel, Inc. | Insulin compositions with improved absorption |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
AU2005228150A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
SE528121C2 (sv) * | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
DK2708225T3 (en) | 2004-04-23 | 2019-04-08 | Cydex Pharmaceuticals Inc | DPI formulation containing sulfoalkyl ether cyclodextrin |
US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
JP5087406B2 (ja) * | 2004-06-04 | 2012-12-05 | アフィニウム ファーマシューティカルズ, インク. | 治療薬ならびにその製造方法および使用方法 |
US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7915281B2 (en) * | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
CN105801686B (zh) | 2004-07-19 | 2020-04-07 | 比奥孔有限公司 | 胰岛素-低聚物共轭物、制剂及其用途 |
WO2006033713A2 (en) * | 2004-08-09 | 2006-03-30 | Chiron Corporation | Methods for ciprofloxacin inhalation |
DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
PL2322180T3 (pl) | 2004-08-23 | 2015-10-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
JPWO2006025395A1 (ja) * | 2004-08-31 | 2008-05-08 | 慶彦 清水 | キャリアフリーの細胞増殖因子を用いた慢性閉塞性肺疾患に対する医薬および処置システム |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
AU2005334514B2 (en) * | 2004-10-29 | 2009-11-26 | President And Fellows Of Harvard College | Particles for treatment of pulmonary infection |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
ES2392647T3 (es) * | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón |
EP1831221B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Substituted chiral fused 1,2 imidazo 4,5-c ring compounds |
US9248127B2 (en) * | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
JP2008530113A (ja) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | オキシムおよびヒドロキシラミン置換イミダゾ[4,5−c]環化合物および方法 |
EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
RS55114B1 (sr) | 2005-05-18 | 2016-12-30 | Raptor Pharmaceuticals Inc | Aerosolizovani fluorohinoloni i njihove upotrebe |
US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
RU2394550C2 (ru) | 2005-09-14 | 2010-07-20 | Маннкайнд Корпорейшн | Способ получения лекарственной композиции, основанный на увеличении сродства поверхностей кристаллических микрочастиц к активным агентам |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
WO2007041481A1 (en) * | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
SI1991201T1 (en) * | 2006-02-10 | 2018-08-31 | Pari Pharma Gmbh | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY |
EP1986674A4 (en) * | 2006-02-13 | 2009-11-11 | Nektar Therapeutics | PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME |
EP1988880A2 (en) * | 2006-02-15 | 2008-11-12 | Tika Läkemedel AB | Stable mixture of corticosteroids |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
EP2012817A2 (en) * | 2006-04-12 | 2009-01-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
ES2386972T3 (es) * | 2006-05-31 | 2012-09-10 | Genzyme Corporation | Uso de polisacáridos para la estimulación de la actividad enzimática |
WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
JP5468899B2 (ja) * | 2006-07-20 | 2014-04-09 | アフィニウム ファーマシューティカルズ, インク. | Fabiインヒビターとしてのアクリルアミド誘導体 |
FR2904532B1 (fr) * | 2006-08-03 | 2012-10-19 | Soc Extraction Principes Actif | Composition dermatologique et/ou cosmetique contenant des polypeptides ou des peptides |
WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
JP5265545B2 (ja) * | 2006-09-01 | 2013-08-14 | シーエスエル、リミテッド | 免疫応答を誘発または誘導する方法 |
US8263613B2 (en) * | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
WO2008124522A2 (en) * | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
US8747872B2 (en) * | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
JP5537425B2 (ja) * | 2007-06-26 | 2014-07-02 | メルク・シャープ・アンド・ドーム・コーポレーション | 凍結乾燥抗真菌組成物 |
US8551534B2 (en) * | 2007-10-10 | 2013-10-08 | Parion Sciences, Inc. | Inhaled hypertonic saline delivered by a heated nasal cannula |
JP2011500514A (ja) * | 2007-10-12 | 2011-01-06 | シーエスエル、リミテッド | 汎発流行性インフルエンザウィルスに対する免疫応答を惹起する方法 |
MX2010007342A (es) * | 2008-01-04 | 2010-08-26 | Biodel Inc | Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
WO2009143011A1 (en) * | 2008-05-20 | 2009-11-26 | Novartis Ag | Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
HUE027973T2 (en) | 2008-06-13 | 2016-11-28 | Mannkind Corp | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8680263B2 (en) * | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
WO2010036945A2 (en) * | 2008-09-26 | 2010-04-01 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
CA2739893C (en) | 2008-10-07 | 2016-10-04 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
CN105520922A (zh) | 2008-10-07 | 2016-04-27 | 拉普特制药有限公司 | 用于改进的药物动力学的氟喹诺酮气雾剂制剂 |
WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
ES2625260T5 (es) | 2009-03-26 | 2020-07-29 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares |
US9539233B2 (en) * | 2009-05-04 | 2017-01-10 | Aridis Pharmaceuticals Inc. | Gallium formulation for the treatment and prevention of infectious diseases |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
HUE047834T2 (hu) | 2009-05-29 | 2020-05-28 | Pearl Therapeutics Inc | Nyújtott hatású muszkarin antagonisták és nyújtott hatású béta 2 adrenerg receptor agonisták pulmonáris beadására alkalmas készítmények és ezekkel kapcsolatos eljárások és rendszerek |
CA2764759A1 (en) | 2009-06-09 | 2010-12-16 | Defyrus, Inc. | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
KR20210027546A (ko) | 2009-06-12 | 2021-03-10 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
BR112012004692B8 (pt) | 2009-09-04 | 2021-05-25 | Mpex Pharmaceuticals Inc | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
US9072783B2 (en) | 2009-11-18 | 2015-07-07 | Aridis Pharmaceuticals | Highly dispersible powders, compositions and methods for preparation |
ES2625331T3 (es) * | 2009-12-21 | 2017-07-19 | Glanbia Nutritionals (Ireland) Ltd. | Composición de leucina/péptido y procedimiento de formulación |
DK2947148T3 (en) * | 2010-04-20 | 2017-09-18 | Octapharma Ag | NEW STABILIZER FOR PHARMACEUTICAL PROTEINS |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
WO2012030647A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
CN105640925B (zh) | 2010-08-30 | 2019-08-16 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
CA2812414C (en) | 2010-09-29 | 2020-09-22 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
ES2710537T3 (es) | 2010-09-29 | 2019-04-25 | Pulmatrix Operating Co Inc | Polvos secos catiónicos |
ES2630012T3 (es) | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
JP6034798B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 液体ウイルス製剤 |
US8709310B2 (en) | 2011-01-05 | 2014-04-29 | Hospira, Inc. | Spray drying vancomycin |
US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US10358043B2 (en) * | 2011-03-31 | 2019-07-23 | Elite Power Solutions, LLC | Golf cart battery system |
DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
EP2709646A4 (en) * | 2011-05-19 | 2015-05-13 | Savara Inc | DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS |
US9572774B2 (en) * | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
KR101792473B1 (ko) | 2011-06-07 | 2017-10-31 | 아사히 가세이 파마 가부시키가이샤 | 고순도 pth 함유 동결 건조 제제 및 그의 제조 방법 |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
US8778383B2 (en) | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
MX2014007277A (es) | 2011-12-16 | 2014-07-28 | Novartis Ag | Aparato de aerosolizacion para administracion de farmaco independiente del perfil de inhalacion. |
WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
KR101342485B1 (ko) * | 2012-02-29 | 2013-12-17 | 미원상사주식회사 | 트리펩타이드 및 이를 함유하는 노화방지, 주름개선, 미백 및 항염효능의 화장료 조성물 |
WO2013176622A1 (en) * | 2012-05-21 | 2013-11-28 | Agency For Science, Technology And Research (A*Star) | A dry powder formulation |
SG11201407867VA (en) | 2012-05-29 | 2014-12-30 | Parion Sciences Inc | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
CN104684922B (zh) | 2012-06-19 | 2016-10-26 | 德彪药业国际股份公司 | (e)-n-甲基-n-((3-甲基苯并呋喃-2-基)甲基)-3-(7-氧代-5,6,7,8-四氢-1,8-萘啶-3-基)丙烯酰胺的前药衍生物 |
RU2650035C2 (ru) | 2012-07-12 | 2018-04-06 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
CN108484513A (zh) | 2012-12-17 | 2018-09-04 | 帕里昂科学公司 | 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物 |
SG11201507564PA (en) | 2013-03-15 | 2015-10-29 | Mannkind Corp | Microcrystalline diketopiperazine compositions and methods |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
KR102275109B1 (ko) | 2013-03-15 | 2021-07-07 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
PE20160155A1 (es) | 2013-05-22 | 2016-04-01 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos |
EP3027026A4 (en) | 2013-07-31 | 2017-05-03 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
EP3091976A4 (en) | 2014-01-10 | 2017-10-11 | Genoa Pharmaceuticals Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
ES2924988T3 (es) | 2014-10-10 | 2022-10-13 | Univ Michigan Regents | Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria |
JP6998881B2 (ja) | 2016-02-26 | 2022-02-10 | デビオファーム・インターナショナル・エス・アー | 糖尿病性足感染症の処置のための医薬 |
SG11201903287PA (en) | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
JP7265984B2 (ja) | 2016-10-21 | 2023-04-27 | アディマブ, エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
AU2017345786A1 (en) | 2016-10-21 | 2019-05-23 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
CN106727348B (zh) * | 2016-12-20 | 2020-10-13 | 广州中大南沙科技创新产业园有限公司 | 防潮抗湿的低密度载体颗粒及其制备方法和应用 |
WO2018113891A1 (en) * | 2016-12-23 | 2018-06-28 | University Of Copenhagen | A co-amorphous form of a substance and a dipeptide |
JP2022553751A (ja) * | 2019-10-28 | 2022-12-26 | アストラゼネカ・アクチエボラーグ | ロイシン及びトリロイシンを含む乾燥粉末製剤 |
IL292437A (en) | 2019-10-28 | 2022-06-01 | Medimmune Ltd | Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them |
CA3226153A1 (en) | 2021-07-09 | 2023-01-12 | Astrazeneca Pharmaceuticals Lp | Compositions, methods and systems for aerosol drug delivery |
US20230053812A1 (en) * | 2021-07-27 | 2023-02-23 | Aurobindo Pharma Ltd | Stable peptide formulations for oral use |
WO2023091081A2 (en) * | 2021-11-16 | 2023-05-25 | Agency For Science, Technology And Research | Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
WO2023229023A1 (ja) * | 2022-05-25 | 2023-11-30 | 学校法人 名城大学 | 粉末剤及びその製造方法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2224175B1 (zh) | 1973-04-04 | 1978-04-14 | Isf Spa | |
IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
FR2519988B1 (fr) | 1982-01-20 | 1985-06-14 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
GB8314308D0 (en) | 1983-05-24 | 1983-06-29 | Matburn Holdings Ltd | Medical administration devices |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4668281A (en) | 1985-05-20 | 1987-05-26 | E. I. Du Pont De Nemours And Company | Thiophenesulfonamides |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
US5519049A (en) | 1989-06-06 | 1996-05-21 | Fisons Plc | Macrolides for the treatment of reversible obstructive airways diseases |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
IT1243344B (it) | 1990-07-16 | 1994-06-10 | Promo Pack Sa | Inalatore plurimonodose per medicamenti in polvere |
ZA918014B (en) | 1990-11-05 | 1992-07-29 | Squibb & Sons Inc | Heteroaroyl derivatives of monocyclic beta-lactam antibiotics |
KR100246082B1 (ko) | 1991-07-02 | 2000-04-01 | 인헤일, 인코오포레이티드 | 에어로졸화된약제를전달하는방법및장치 |
US5320094A (en) | 1992-01-10 | 1994-06-14 | The Johns Hopkins University | Method of administering insulin |
ZA93929B (en) | 1992-02-18 | 1993-09-10 | Akzo Nv | A process for the preparation of biologically active materialcontaining polymeric microcapsules. |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
GB9218027D0 (en) | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
IS1736B (is) | 1993-10-01 | 1999-12-30 | Astra Ab | Aðferð og tæki sem stuðla að aukinni samloðun agna |
US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
MX9605717A (es) | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
PL188625B1 (pl) | 1994-09-21 | 2005-03-31 | Nektar Therapeutics | Sposób wytwarzania aerozolu ze sproszkowanego leku, urządzenie do wytwarzania aerozolu ze sproszkowanego leku i pojemnik do przechowywania sproszkowanego leku |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5667068A (en) * | 1995-06-13 | 1997-09-16 | Weaver; Stevie W. | Protective cover for an endoscope |
GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
TW403653B (en) | 1995-12-25 | 2000-09-01 | Otsuka Pharma Co Ltd | Dry compositions |
US20030138402A1 (en) | 1995-12-25 | 2003-07-24 | Otsuka Pharmaceutical Co., Ltd. | Dry compositions |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5826633A (en) | 1996-04-26 | 1998-10-27 | Inhale Therapeutic Systems | Powder filling systems, apparatus and methods |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
AU6014098A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Aerosolized hydrophobic drug |
US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
WO2000061178A1 (en) * | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
AU779869B2 (en) * | 1999-04-13 | 2005-02-17 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
-
2000
- 2000-04-12 DE DE60025019T patent/DE60025019T2/de not_active Expired - Lifetime
- 2000-04-12 KR KR1020027005391A patent/KR100702878B1/ko not_active IP Right Cessation
- 2000-04-12 AU AU42353/00A patent/AU775565B2/en not_active Ceased
- 2000-04-12 HU HU0301851A patent/HU229310B1/hu not_active IP Right Cessation
- 2000-04-12 PT PT05027610T patent/PT1666028E/pt unknown
- 2000-04-12 AT AT00922117T patent/ATE313318T1/de active
- 2000-04-12 IL IL14908500A patent/IL149085A0/xx active IP Right Grant
- 2000-04-12 AT AT05027610T patent/ATE461692T1/de active
- 2000-04-12 ES ES00922117T patent/ES2254164T3/es not_active Expired - Lifetime
- 2000-04-12 DK DK05027610.4T patent/DK1666028T3/da active
- 2000-04-12 CN CNB008149895A patent/CN1188111C/zh not_active Expired - Fee Related
- 2000-04-12 WO PCT/US2000/009785 patent/WO2001032144A1/en not_active Application Discontinuation
- 2000-04-12 EP EP00922117A patent/EP1223915B1/en not_active Expired - Lifetime
- 2000-04-12 ES ES05027610T patent/ES2343124T3/es not_active Expired - Lifetime
- 2000-04-12 EP EP05027610A patent/EP1666028B1/en not_active Expired - Lifetime
- 2000-04-12 NZ NZ518401A patent/NZ518401A/en not_active IP Right Cessation
- 2000-04-12 DE DE60044070T patent/DE60044070D1/de not_active Expired - Lifetime
- 2000-04-12 DK DK00922117T patent/DK1223915T3/da active
- 2000-04-12 TW TW089106941A patent/TWI310688B/zh not_active IP Right Cessation
- 2000-04-12 MX MXPA02004193A patent/MXPA02004193A/es active IP Right Grant
- 2000-04-12 JP JP2001534349A patent/JP4859320B2/ja not_active Expired - Fee Related
- 2000-04-12 CA CA002389219A patent/CA2389219C/en not_active Expired - Fee Related
- 2000-04-13 US US09/548,759 patent/US6518239B1/en not_active Expired - Lifetime
-
2002
- 2002-04-11 IL IL149085A patent/IL149085A/en not_active IP Right Cessation
- 2002-04-17 NO NO20021800A patent/NO332144B1/no not_active IP Right Cessation
- 2002-12-06 US US10/313,343 patent/US6835372B2/en not_active Expired - Lifetime
-
2004
- 2004-11-10 US US10/985,509 patent/US7482024B2/en not_active Expired - Lifetime
-
2006
- 2006-09-22 HK HK06110590.7A patent/HK1092687A1/xx not_active IP Right Cessation
-
2008
- 2008-12-23 US US12/343,365 patent/US8501240B2/en not_active Expired - Fee Related
-
2010
- 2010-06-22 CY CY20101100575T patent/CY1110136T1/el unknown
- 2010-12-28 JP JP2010294308A patent/JP2011093922A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105451716A (zh) * | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CN109310622A (zh) * | 2016-06-30 | 2019-02-05 | 菲利普莫里斯生产公司 | 尼古丁颗粒和组合物 |
WO2022148418A1 (zh) * | 2021-01-08 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1188111C (zh) | 分散性得到改进的干粉组合物 | |
CN1446077A (zh) | 具有最小聚集的可吸入喷雾干燥4-螺旋束蛋白粉剂 | |
JP2003513031A5 (zh) | ||
KR102321339B1 (ko) | 열-안정성 건조 분말 약제학적 조성물 및 방법 | |
CN1694689A (zh) | 供吸入的缓释多孔微粒 | |
CZ359998A3 (cs) | Způsob výroby dispergovatelných suchých prášků biologických makromolekul, jejich použití pro inhalaci a jednotková dávka makromolekuly | |
CN1518441A (zh) | 具有快速释放性质的吸入式微粒 | |
CN1441670A (zh) | 高效输送大量治疗性气雾剂 | |
CN1607941A (zh) | 粒状药物组合物 | |
CN1317977A (zh) | 干粉活性剂肺部给药 | |
EP2611416B1 (en) | Pharmaceutical composition suitable for use in a dry powder inhaler | |
CN1672731A (zh) | 一种用于肺部给药的干扰素粉雾剂及其制备方法 | |
CN1168496C (zh) | 胰岛素肺部给药的粉雾剂及其制备方法 | |
CN1642533A (zh) | 吸入用粉末医药组合物及其制备方法 | |
CN1439360A (zh) | 有效部位药物沉积得到改善的干粉组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NEKTA MEDICINES INC Free format text: FORMER OWNER: INHALE THERAPEUTICS SYSTEMS, INC. Effective date: 20030521 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030521 Address after: California, USA Applicant after: INHALE THERAPEUTIC SYSTEMS, Inc. Address before: California, USA Applicant before: INHALE THERAPEUTIC SYSTEMS, Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NOVARTIS AG Free format text: FORMER OWNER: NOVARTIS INTERNATIONAL AG CO., LTD. Effective date: 20100513 Owner name: NOVARTIS INTERNATIONAL AG CO., LTD. Free format text: FORMER OWNER: NEKTA MEDICINES INC. Effective date: 20100513 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: CALIFORNIA, U.S. TO: BASEL, SWITZERLAND |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100513 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: Nova pharmaceuticals Effective date of registration: 20100513 Address after: Basel, Switzerland Patentee after: Nova pharmaceuticals Address before: California, USA Patentee before: INHALE THERAPEUTIC SYSTEMS, Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050209 Termination date: 20180412 |